Costs and consequences of botulinum toxin type A use: Management of children with cerebral palsy in Germany

European Journal of Health Economics

Volumn 5, Issue 3, 2004, Pages 227-235

  Ruiz, Francis J ^a   Guest, Julian F ^a   Lehmann, Almut ^a   Davie, Alison M ^a   Güttler, Karen ^a   Schlüter, Olaf ^a   Dreiss, Götz ^b  

^a CATALYST Health Economics Consultants   (United Kingdom)

^b DRK Krankenhaus Seepark   (Germany)

Author keywords

Botulinum toxin; Cerebral palsy; Costs; Economics; Germany; Paediatrics; Resource use

Indexed keywords

ANALGESIC AGENT; ANESTHETIC AGENT; ANTIASTHMATIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; BOTULINUM TOXIN A; HYPNOTIC SEDATIVE AGENT; LAXATIVE; MUSCLE RELAXANT AGENT; SPASMOLYTIC AGENT;

CEREBRAL PALSY; CLINICAL TRIAL; DATA ANALYSIS; GERMANY; HEALTH SERVICE; HEALTH SURVEY; HOSPITAL ADMISSION; HUMAN; MEDICAL ETHICS; PATIENT SELECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW;

ADOLESCENT; BOTULINUM TOXIN TYPE A; CEREBRAL PALSY; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COSTS AND COST ANALYSIS; FEMALE; GERMANY; HEALTH RESOURCES; HUMANS; LENGTH OF STAY; MALE; MULTIVARIATE ANALYSIS; NEUROMUSCULAR AGENTS; PATIENT SELECTION; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 6044233420     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-004-0224-7     Document Type: Review

References (39)

1. Albright AL (1996) Baclofen in treatment of cerebral palsy. J Child Neurol 11:77-83
2. Arroyave Loaiza G, Jarillo Soto EC, Garfias Garnica MG, Ribera Ibarra DB, Uribe Zamarripa JA (2000) Cost-benefit of the pharmacologic treatment of cerebral palsy with spasticity in Mexico. Rev Esp Salud Publica 74:549-559
3. Bjornson KF, McLaughlin JF (2001) The measurement of health-related quality of life (HRQL) in children with cerebral palsy. Eur J Neurol 8 [Suppl 5]:183-193
4. Bodensteiner JB (1996) The management of cerebral palsy: subjectivity and a conundrum. J Child Neurol 11:75-76
5. Boyd RN, Hays RM (2001) Current evidence for the use of botulinum toxin type A in the management of children with cerebral palsy: a systematic review. Eur J Neurol 8 [Suppl 5]:1-20
6. Cheng JC, So WS (1993) Percutaneous elongation of the Achilles tendon in children with cerebral palsy. Int Orthop 17:162-165
7. Copp ER, Harris R, Keenan J (1970) Peripheral nerve block and motor point block with phenol in the management of spasticity. Proc R Soc Med 63:937-938
8. Cusick BD (1988) Splints and casts. Managing foot deformity in children with neuromotor disorders. Phys Ther 68:1903-1912
9. Dabney KW, Lipton GE, Miller F (1997) Cerebral palsy. Curr Opin Pediatr 9:81-88
10. Dursun N, Dursun E, Alican D (2002) The role of botulinum toxin a in the management of lower limb spasticity in patients with cerebral palsy. Int J Clin Pract 56:564-567
11. Elmer EB, Wenger DR, Mubarak SJ, Sutherland DH (1992) Proximal hamstring lengthening in the sitting cerebral palsy patient. J Pediatr Orthop 12:329-336
12. Fehlings D, Rang M, Glazier J, Steele C (2001) Botulinum toxin type A injections in the spastic upper extremity of children with hemiplegia: child characteristics that predict a positive outcome. Eur J Neurol 8 [Suppl 5]:145-149
13. Flett P (2003) Rehabilitation of spasticity and related problems in childhood cerebral palsy. J Paediatr Child Health 39:6-14
14. Graham HK, Aoki KR, Autti-Ramo I, Boyd RN, Delgado MR, Gaebler-Spira DJ, Gormley ME, Guyer BM, Heinen F, Holton AF, Matthews D, Molenaers G, Motta F, Garcia Ruiz PJ, Wissel J (2000) Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture 11:67-79
15. Graham HK, Boyd RN, Fehlings D (2003) Does intramuscular botulinum toxin A injection improve upper-limb function in children with hemiplegic cerebral palsy? Med J Aust 178:95-96
16. Graves P (1995) Therapy methods for cerebral palsy. J Paediatr Child Health 31:24-28
17. Greene WB (1987) Achilles tendon lengthening in cerebral palsy: comparison of in patient versus ambulatory surgery. J Pediatr Orthop 7:256-258
18. Green C, Proch C, Gara SE (1997) The changing face of cerebral palsy: a review of the disorder and its treatment. J Neurol Rehabil 11:245-253
19. Griffith ER, Melampy CN (1977) General anesthesia use in phenol intramuscular neurolysis in young children with spasticity. Arch Phys Med Rehabil 58:154-157
20. Houltram J, Noble I, Boyd RN, Corry I, Flett P, Graham HK (2001) Botulinum toxin type A in the management of equinus in children with cerebral palsy: an evidence-based economic evaluation. Eur J Neurol 8 [Suppl 5]:194-202
21. Hur JJ (1995) Review of research on therapeutic interventions for children with cerebral palsy. Acta Neurol Scand 91:423-432
22. Hurvitz EA, Conti GE, Brown SH (2003) Changes in movement characteristics of the spastic upper extremity after botulinum toxin injection. Arch Phys Med Rehabil 84:444-454
23. Kagaya H, Yamada S, Nagasawa T, Ishihara Y, Kodama H, Endoh H (1996) Split posterior tibial tendon transfer for varus deformity of hindfoot. Clin Orthop 323:254-260
24. Kaufman HH, Bodensteiner J, Burkart B, Gutmann L, Kopitnik T, Hochberg V, Loy N, Cox-Ganser J, Hobbs G (1994) Treatment of spastic gait in cerebral palsy. W V Med J 90:190-192
25. Koman LA, Brashear A, Rosenfeld S, Chambers H, Russman B, Rang M, Root L, Ferrari E, Garcia de Yebenes Prous J, Smith BP, Turkel C, Walcott JM, Molloy PT (2001) Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial. Pediatrics 108:1062-1071
26. Little WJ (1966) On the influence of abnormal parturition, difficult labours, premature birth, and asphyxia neonatorum, on the mental and physical condition of the child, especially in relation to deformities. Clin Orthop 46:7-22
27. Lou HC (1994) Hypoxic-hemodynamic pathogenesis of brain lesions in the newborn. Brain Dev 16:423-431
28. Metaxiotis D, Siebel A, Doederlein L (2002) Repeated botulinum toxin A injections in the treatment of spastic equinus foot. Clin Orthop 394:177-185
29. Moreau MJ, Lake DM (1987) Outpatient percutaneous heel cord lengthening in children. J Pediatr Orthop 7:253-255
30. Mundenbruch R (1999) Einheitlicher Bewertungsmasstab 2001. Zauner Druck- und Verlagsanstalt, Dachau
31. Norlin R, Tkaczuk H (1992) One session surgery on the lower limb in children with cerebral palsy. A five year follow-up. Int Orthop 16:291-293
32. O'Brien CF (2002) Treatment of spasticity with botulinum toxin. Clin J Pain 18[6 Suppl]:S182-190
33. Pharoah PO, Cooke T, Johnson MA, King R, Mutch L (1998) Epidemiology of cerebral palsy in England and Scotland, 1984-9. Arch Dis Child Fetal Neonatal Ed 79:F21-25
34. Pierson SH, Katz DI, Tarsy D (1996) Botulinum toxin A in the treatment of spasticity: functional implications and patient selection. Arch Phys Med Rehabil 77:717-721
35. Reddihough DS, King JA, Coleman GJ, Fosang A, McCoy AT, Thomason P, Graham HK (2002) Functional outcome of botulinum toxin A injections to the lower limbs in cerebral palsy. Dev Med Child Neurol 44:820-827
36. Rote Liste (2002) Bundesverband der Pharmazeutischen Industrie. Editio Cantor, Aulendorf
37. Wallace JD (1994) Summary of combined clinical analysis of controlled clinical trials with tizanidine. Neurology 44[11 Suppl 9]:S60-68; discussion S68-69
38. Wilke MH, Hocherl E, Scherer J, Janke L (2001) Introducing the new DRG-based payment system in German hospitals - a difficult operation? HEPAC 2:79-85
39. Yang TF, Fu CP, Kao NT, Chan RC, Chen SJ (2003) Effect of botulinum toxin type a on cerebral palsy with upper limb spasticity. Am J Phys Med Rehabil 82:284-289